ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
89.95
-4.45 (-4.71%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close94.40
Open93.22
Bid0.00 x 800
Ask0.00 x 900
Day's Range87.76 - 93.28
52 Week Range69.38 - 125.86
Volume19,747,219
Avg. Volume8,343,131
Market Cap136.19B
Beta1.67
PE Ratio (TTM)22.62
EPS (TTM)3.98
Earnings DateJul 27, 2018
Forward Dividend & Yield3.84 (3.96%)
Ex-Dividend Date2018-07-12
1y Target Est113.05
Trade prices are not sourced from all markets
  • AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'
    Bloomberg12 hours ago

    AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'

    Citron tweeted Thursday that AbbVie was “the next great drug short” and that its 12-month price target was $60. The drug is protected by a robust wall of patents that several companies have  failed to batter down.

  • Why AbbVie Shares Are Sliding Today
    InvestorPlace13 hours ago

    Why AbbVie Shares Are Sliding Today

    AbbVie (NYSE:ABBV) stock took a hit today following comments concerning biosimilars.Source: Shutterstock

  • Investopedia15 hours ago

    How AbbVie Makes its Money

    Devised as the research arm of Abbott and based in Chicago, AbbVie became a major pharmaceutical company in its own right in 2013. The diminished Abbott now retains the non-research interests – everything from baby formula to sports nutrition to heart stents. As for AbbVie and its separation from its progenitor, management claimed that the move gave investors a chance to objectively value two businesses that were heading in disparate directions.

  • Barrons.com15 hours ago

    AbbVie's Tumble May Not Last

    The drug maker's shares are tumbling on two factors: First is the Department of Health and Human Services's proposal for the Office of Management and Budget to advance with the process of revising regulations that have allowed pharmaceutical companies to offer insurers and pharmacy-benefit managers rebates. Evercore ISI's Joshua Schimmer isn't overly worried yet.

  • Benzinga15 hours ago

    AbbVie's Stock Hit By Citron Tweet

    In a speech on Wednesday, U.S. Food and Drug Administration commissioner Scott Gottlieb ripped drug makers for blocking competitors from bringing potentially cheaper biosimilar drugs to the market. On ...

  • ACCESSWIRE16 hours ago

    3 Biotech Stocks to Watch This Quarter

    CORAL GABLES, FL / ACCESSWIRE / July, 19 2018 / President Trump continues to put down the pharmaceutical industry on a regular basis, despite this biotech stocks are doing well over the last year. Since ...

  • MarketWatch17 hours ago

    AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short'

    AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.

  • Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
    Zacks17 hours ago

    Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

    On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance

  • 3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola
    InvestorPlace19 hours ago

    3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola

    American Express Company (NYSE:AXP) was arguably the day’s biggest story, with shares up 1.8% headed into its post-close earnings report, though fell 2.7% after hours when revenue fell short of estimates. International Business Machines (NYSE:IBM) took a different path. To that end, Coca-Cola (NYSE:KO), AbbVie (NYSE:ABBV) and McDonald’s (NYSE:MCD) are lining up as Thursday’s top prospects.

  • TheStreet.comyesterday

    3 'Strong Buy' Healthcare Stocks Poised to Surge

    Bring on healthcare earnings season. Ahead of earnings season for the group, we have selected three healthcare stocks beating the market in 2018. Using TipRanks' Stock Screener tool, we quickly discovered the best-rated stocks, filtering by "best analyst consensus" stocks in the healthcare sector.

  • Drugmakers Game the Patent System and Reap Billions, FDA Says
    Bloomberg2 days ago

    Drugmakers Game the Patent System and Reap Billions, FDA Says

    Efforts by drugmakers to thwart less-expensive rivals for pricey biologic medicines cost the U.S. health-care system billions of dollars last year, the Food and Drug Administration’s chief said in laying out a plan to end such practices. It plans to work with the Federal Trade Commission to stop “gaming tactics” like piling up patents to extend the commercial dominance of brand-name medicines, FDA Commissioner Scott Gottlieb said in a speech on Wednesday in Washington. Gottlieb said he also wants Congress’s help to close any loopholes that enable drugmakers to hinder competition from so-called biosimilars.

  • AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
    Zacks2 days ago

    AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.

    AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.

  • Reuters3 days ago

    Mylan signs U.S. license deal on Humira with AbbVie

    AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. The deal is in line with AbbVie's strategy to fend off rivals of the world's best-selling prescription drug until 2023, giving the company more time to bolster its pipeline with new cash cows to offset the expected sales decline. Humira, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie's net revenue.

  • PR Newswire3 days ago

    AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan

    NORTH CHICAGO, Ill., July 17, 2018 /PRNewswire/ -- AbbVie (ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property, excluding Europe.

  • 3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018
    Motley Fool5 days ago

    3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018

    Forget what's happened so far in 2018. These big pharma stocks look like great picks for the rest of the year.

  • AbbVie Announces Collaborations with Calico and Calibr
    Market Realist6 days ago

    AbbVie Announces Collaborations with Calico and Calibr

    Calico is a life sciences company focused on aging research and therapeutics. Together, AbbVie and Calico have produced more than two dozen early-stage programs for disease states across oncology and neuroscience since 2014. The agreement has extended the AbbVie-Calico collaboration for three years.

  • AbbVie’s Supplemental New Drug Application for Venetoclax
    Market Realist6 days ago

    AbbVie’s Supplemental New Drug Application for Venetoclax

    On July 12, AbbVie (ABBV) announced that it had submitted an sNDA (supplemental new drug application) to the FDA for venetoclax for treating newly diagnosed AML (acute myeloid leukemia) patients not eligible for intensive chemotherapy. AML is an aggressive form of cancer with very low rates of survival and few available options for patients who are ineligible for intensive chemotherapy. The FDA has granted the drug two breakthrough therapy designations for AML.

  • 5 Big Pharma Stocks Investors Love Right Now
    InvestorPlace7 days ago

    5 Big Pharma Stocks Investors Love Right Now

    News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.

  • Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?
    Zacks7 days ago

    Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?

    The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2

  • Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
    Zacks7 days ago

    Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

    Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

  • 2 Overlooked Biotech Stocks to Buy Now
    Motley Fool7 days ago

    2 Overlooked Biotech Stocks to Buy Now

    The industry's biggest players just aren't getting the attention their cash flows deserve.

  • TheStreet.com7 days ago

    3 Pharma Stocks Goldman Sachs Sees as Buys

    Stagnant deal activity has investors "losing patience with the large cap pharma sector," according to a note from Goldman Sachs analyst Jami Rubin. Small- and mid-cap biotech companies are being valued at all time highs, and companies are staying away from new acquisitions for fear of paying high premiums for them, Rubin wrote. "Pharma management teams are facing investor pressure to put their capital to work, but balancing the risk of overpaying with the risk of doing nothing has led to low levels of deal activity thus far this year in our view," Rubin said.

  • AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
    Zacks8 days ago

    AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

    AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

  • J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
    Zacks8 days ago

    J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?

    The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.

  • Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet
    Motley Fool8 days ago

    Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet

    It's still really early for research from the collaboration between AbbVie and Alphabet's Calico, but the payoff could be huge.